Compare SRL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRL | ENTX |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 74.7M |
| IPO Year | N/A | 2018 |
| Metric | SRL | ENTX |
|---|---|---|
| Price | $9.01 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 35.6K | ★ 264.8K |
| Earning Date | 04-24-2026 | 11-14-2025 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,224,099.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $5.13 | $1.44 |
| 52 Week High | $9.64 | $3.22 |
| Indicator | SRL | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 32.54 |
| Support Level | $8.78 | $1.52 |
| Resistance Level | $9.45 | $1.59 |
| Average True Range (ATR) | 0.57 | 0.13 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 74.20 | 0.00 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.